Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice

被引:88
作者
Campos-Neto, A
Webb, JR
Greeson, K
Coler, RN
Skeiky, YAW
Reed, SG
机构
[1] Infect Dis Res Inst, Seattle, WA 98104 USA
[2] Corixa Corp, Seattle, WA USA
[3] Med Sch Itajuba, Itajuba, MG, Brazil
[4] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada
关键词
D O I
10.1128/IAI.70.6.2828-2836.2002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have recently shown that a cocktail containing two leishmanial recombinant antigens (LmSTI1 and TSA) and interleukin-12 (IL-12) as an adjuvant induces solid protection in both a murine and a nonhuman primate model of cutaneous leishmaniasis. However, because IL-12 is difficult to prepare, is expensive. and does not have the stability required for a vaccine product, we have investigated the possibility of using DNA as an alternative means of inducing protective immunity. Here, we present evidence that the antigens TSA and LmSTI1 delivered in a plasmid DNA format either as single genes or in a tandem digene construct induce equally solid protection against Leishmania major infection in susceptible BALB/c mice. Immunization of mice with either TSA DNA or LmSTI1 DNA induced specific CD4(+)-T-cell responses of the Th1 phenotype without a requirement for specific adjuvant. CD8 responses, as measured by cytotoxic-T-lymphocyte activity, were generated after immunization with TSA DNA but not LmSTI1 DNA. Interestingly, vaccination of mice with TSA DNA consistently induced protection to a much greater extent than LmSTI1 DNA, thus supporting the notion that CD8 responses might be an important accessory arm of the immune response for acquired resistance against leishmaniasis. Moreover, the protection induced by DNA immunization was specific for infection with Leishmania, i.e., the immunization had no effect on the course of infection of the mice challenged,with an unrelated intracellular pathogen such as Mycobacterium tuberculosis. Conversely, immunization of BALB/c mice with a plasmid DNA that is protective against challenge with M. tuberculosis had no effect on the course of infection of these mice with L. major. Together, these results indicate that the protection observed with the leishmanial DNA is mediated by acquired specific immune response rather than by the activation of nonspecific innate immune mechanisms. In addition, a plasmid DNA containing a fusion construct of the two genes was also tested. Similarly to the plasmids encoding individual proteins, the fusion construct induced both specific immune responses to the individual antigens and protection against challenge with L. major. These results confirm previous observations about the possibility of DNA immunization against leishmaniasis and lend support to the idea of using a single polygenic plasmid DNA construct to achieve polyspecific immune responses to several distinct parasite antigens.
引用
收藏
页码:2828 / 2836
页数:9
相关论文
共 59 条
[1]   Mediterranean leishmaniasis in HIV-infected patients: Epidemiological, clinical, and diagnostic features of 22 cases [J].
Agostoni, C ;
Dorigoni, N ;
Malfitano, A ;
Caggese, L ;
Marchetti, G ;
Corona, S ;
Gatti, S ;
Scaglia, M .
INFECTION, 1998, 26 (02) :93-99
[2]   DNA vaccines: Technology and application as anti-parasite and anti-microbial agents [J].
Alarcon, JB ;
Waine, GW ;
McManus, DP .
ADVANCES IN PARASITOLOGY, VOL 42, 1999, 42 :343-410
[3]   Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition [J].
Bauer, S ;
Kirschning, CJ ;
Häcker, H ;
Redecke, V ;
Hausmann, S ;
Akira, S ;
Wagner, H ;
Lipford, GB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9237-9242
[4]   Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease [J].
Campos-Neto, A ;
Porrozzi, R ;
Greeson, K ;
Coler, RN ;
Webb, JR ;
Seiky, YAW ;
Reed, SG ;
Grimaldi, G .
INFECTION AND IMMUNITY, 2001, 69 (06) :4103-4108
[5]   Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis [J].
Coler, RN ;
Campos-Neto, A ;
Ovendale, P ;
Day, FH ;
Fling, SP ;
Zhu, LQ ;
Serbina, N ;
Flynn, JL ;
Reed, SG ;
Alderson, MR .
JOURNAL OF IMMUNOLOGY, 2001, 166 (10) :6227-6235
[6]  
Compos-Neto A, 1998, J IMMUNOL, V160, P2037
[7]  
Conceicao Silva Fatima D., 1994, European Journal of Immunology, V24, P2813
[8]   LEISHMANIA-REACTIVE CD4+ AND CD8+ T-CELLS ASSOCIATED WITH CURE OF HUMAN CUTANEOUS LEISHMANIASIS [J].
DACRUZ, AM ;
CONCEICAOSILVA, F ;
BERTHO, AL ;
COUTINHO, SG .
INFECTION AND IMMUNITY, 1994, 62 (06) :2614-2618
[9]   Leishmania, Trypanosoma and moxoneous trypanosomatids as emerging opportunistic agents [J].
Dedet, JP ;
Pratlong, F .
JOURNAL OF EUKARYOTIC MICROBIOLOGY, 2000, 47 (01) :37-39
[10]   Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp160 envelope proteins [J].
Deml, L ;
Schirmbeck, R ;
Reimann, J ;
Wolf, H ;
Wagner, R .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1999, 37 (03) :199-204